GMB and Unite say 350 job cuts in R&D at Chesire facility will damage UK industry, although ABPI remains optimistic
Diabetes portfolio encourages 12 per cent increase in revenues for Denmark-based firm
Gains in diabetes division, but generics pose threat for 2012
Former Savient CEO and Lilly senior VP John Johnson replaces Gold who remains at Dendreon as executive chair
Appoints Andy Bowman and Gary Burd
New measures will encourage greater transparency and allow patients in any European Member State to report adverse reactions
One million packages of Lo/Ovral-28, Norgestrel and Ethinyl Estradiol voluntarily withdrawn in US after mix-up leads to risk of unwanted pregnancy
Vertex' 'breakthrough' Kalydeco is first treatment to target genetic mutation in the disease
Price of J&J's prostate cancer treatment too high to justify use in UK
Sales, research and supply chain operations among those affected
Swiss firm looks to new products and purchase of Illumina to compensate for revenue decline
Former global head of partnering succeeds Paul Brown
Results come as Astellas records net income increase of 24 per cent in the fiscal third quarter
Sales of antipsychotic Zyprexa fall 44 per cent in fourth quarter
Pharma giant’s fourth quarter hit particularly hard after Lipitor’s November US patent expiry
Charges part of wider anticompetitive behaviour case involving generic perindopril
Former general manager at Mundipharma succeeds Antony Mattessich
EALTH will lobby for greater awareness of the health supply chain sector
Pharma firm confirms advanced discussions with property consortium for sale of Discovery Park
He will be replaced by the drug delivery company’s chief financial officer Peter Grant
Deal watch: A look at the biggest mergers and acquisitions from 2011, including Sanofi's purchase of Genzyme and J&J taking over Synthes
The key to true market access success begins with corporate ownership…
Industry needs to be perceived as a contributor to healthcare solutions not just a cost
Embedding and integrating market access strategies company-wide is key
Modern market access activities need to be evidence-based. But what does this really mean for new products being taken to market around the world?
Currently facing a major financial crisis, Spain's healthcare system is overstretched with autonomous regions owing millions of Euros to suppliers such as the pharma industry
Therapies are facing greater scrutiny to ensure they do not carry increased risk of cardiovascular side effects
How centrally developed advertising campaigns can work in local markets and taking tips from motor industry campaigns can help increase brand engagement
A survey of pharma companies shows they are hiring expert help to cope with the problems of an increasingly fragmented market in the UK
Patients seldom refuse therapy outright, but often show a reluctance to comply. Understanding the reasons for this is the first step to improving their treatment